Home » Stocks » OBLN

Obalon Therapeutics, Inc. (OBLN)

Stock Price: $1.07 USD -0.05 (-4.46%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $1.93 +0.86 (80.37%) Dec 4, 7:59 PM

OBLN Stock Price Chart

Key Info

Market Cap 8.31M
Revenue (ttm) 2.31M
Net Income (ttm) -15.92M
Shares Out 7.73M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $1.07
Previous Close $1.12
Change ($) -0.05
Change (%) -4.46%
Day's Open 1.11
Day's Range 1.06 - 1.14
Day's Volume 8,696,325
52-Week Range 0.65 - 2.02

OBLN Stock News

Insider Monkey - 1 week ago

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which...

GlobeNewsWire - 4 weeks ago

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-f...

GlobeNewsWire - 3 months ago

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastr...

GlobeNewsWire - 4 months ago

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas...

GlobeNewsWire - 5 months ago

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastr...

GlobeNewsWire - 6 months ago

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the f...

GlobeNewsWire - 6 months ago

Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position

GlobeNewsWire - 7 months ago

Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA Obalon reported no device-related serious adverse events (...

GlobeNewsWire - 8 months ago

SAN DIEGO, March 25, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved...

GlobeNewsWire - 8 months ago

No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority No patients or employees have be...

Seeking Alpha - 9 months ago

Obalon Therapeutics, Inc. (OBLN) CEO Bill Plovanic on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™ Company continues to execute on its strategy to ...

GlobeNewsWire - 9 months ago

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved ...

Zacks Investment Research - 10 months ago

Is (OBLN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 11 months ago

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable...

Seeking Alpha - 1 year ago

Obalon Therapeutics, Inc. (OBLN) Management on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Solidified leadership and strengthened financial position in place to leverage the Company’s safe and effective weight loss system in the retail medicine setting Solidified leadership and stre...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gas...

Benzinga - 1 year ago

Shares of Obalon Therapeutics Inc (NASDAQ: OBLN), a developer of novel technologies for weight loss, were advancing strongly Thursday morning.

GlobeNewsWire - 1 year ago

Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. Leading bariatric surgeon and authority in th...

Seeking Alpha - 1 year ago

Obalon Therapeutics Inc (OBLN) Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 7.41% and -78.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 year ago

Shares of micro-cap Obalon Therapeutics Inc (NASDAQ: OBLN) traded higher Tuesday after the company announced it has obtained two new U.S.

Benzinga - 1 year ago

Shares of micro-cap Obalon Therapeutics (traded higher after traders circulated the U.S. patent and trademark office abstract for its Intragastric device.

Benzinga - 1 year ago

Obalon Therapeutics Inc (NASDAQ: OBLN) shares have continued to be volatile — and that's no surprise, given that most low-float, low-volume stocks are susceptible to trader manipulation.

Benzinga - 1 year ago

Obalon Therapeutics Inc. shares rose 60 percent Wednesday morning, triggered by a Seeking Alpha post that said Johnson & Johnson could be making a bid for the company for $8 per share.

Zacks Investment Research - 1 year ago

In the latest trading session, OBALON THERPTCS (OBLN) closed at $0.68, marking a -0.37% move from the previous day.

Benzinga - 1 year ago

Medical technology company Obalon Therapeutics Inc. announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common sto...

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) closed the most recent trading day at $0.42, moving -1.96% from the previous trading session.

Zacks Investment Research - 1 year ago

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About OBLN

Obalon Therapeutics, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the O... [Read more...]

Industry
Medical Devices
IPO Date
Oct 6, 2016
CEO
Andrew Rasdal
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
OBLN
Full Company Profile

Financial Performance

In 2019, OBLN's revenue was $3.28 million, a decrease of -63.95% compared to the previous year's $9.10 million. Losses were -$23.68 million, -36.65% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for OBLN is 0.75, which is a decrease of -29.91% from the latest price.

Price Target
$0.75
(-29.91% downside)